Oppenheimer Sticks to Its Buy Rating for Moleculin Biotech (MBRX)

In a report released today, Kevin DeGeeter from Oppenheimer maintained a Buy rating on Moleculin Biotech (MBRXResearch Report), with a price target of $2.00. The company’s shares closed last Thursday at $0.92.

According to TipRanks.com, DeGeeter is a 5-star analyst with an average return of 26.5% and a 51.7% success rate. DeGeeter covers the Healthcare sector, focusing on stocks such as Interpace Diagnostics Group, Rocket Pharmaceuticals, and Ionis Pharmaceuticals.

Currently, the analyst consensus on Moleculin Biotech is a Moderate Buy with an average price target of $2.50.

See today’s analyst top recommended stocks >>

The company has a one-year high of $1.97 and a one-year low of $0.32. Currently, Moleculin Biotech has an average volume of 5.57M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company, which focuses on the development of oncology drug candidates. Its Annamycin product candidate helps in the treatment of relapsed or refractory acute myeloid leukemia. The company’s preclinical small molecule portfolios focus on the modulation of hard-to-target tumor cell signaling mechanisms and the metabolism of tumors. Moleculin Biotech was founded by Walter V. Klemp, Donald H. Picker and Waldemar Priebe on July 28, 2015 and is headquartered in Houston, TX.